Biosimilar product labels in Europe: what information should they contain?
To discuss current labelling of biosimilars in Europe, the European Biopharmaceutical Enterprises (EBE) and the European Association for Bioindustries (EuropaBio) held a multi-stakeholder workshop on the topic of ‘Biosimilar Labelling’, in Brussels, Belgium on 2 February 2016.
The purpose of the meeting was to gain an understanding of how stakeholders use or consult medicinal product information, and to investigate their preferences for the content of biosimilar labels. The focus of discussions was on the perspectives of the end users, namely patients, pharmacists and physicians.
The discussion concerning labelling particulars are outlined in the GaBi Journal article available here.